SynthesisArthritis care & research2021
Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid Arthritis.
Synthesis in Arthritis care & research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Pooled it
- Effects of omega-3 supplementation on lipid metabolism, inflammation, and disease activity in rheumatoid arthritis: a meta-analysis of randomized controlled trials.Clinical rheumatology · 2024Pooled it
- Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).Annals of the rheumatic diseases · 2023Trial
- Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).Annals of the rheumatic diseases · 2023Trial
- Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE.Rheumatology (Oxford, England) · 2023Trial
- The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis.RMD open · 2022Trial
- Article
- Beyond Disease Activity: Fatigue and Health-Related Quality of Life in Rheumatoid Arthritis Remission and Low Disease Activity.Journal of clinical medicine · 2026Article
- Fatigue beyond inflammation in inflammatory rheumatic diseases: a narrative review and treatable-traits framework.Rheumatology international · 2026Review
- Relationship among symptoms of anxiety, psychosomatic, and coping in adults with rheumatoid arthritis.Scientific reports · 2026Article
- Achievement and Maintenance of Remission with Upadacitinib in Patients with Moderate-to-Severe Rheumatoid Arthritis in Italy: 1-Year Data from UPHOLD, a Prospective Real-World Observational Study.Rheumatology and therapy · 2026Article
- Patient-Physician Discordance and Unmet Needs in Rheumatoid Arthritis: A Network Analysis of Clinical and Quality-of-Life Domains.Journal of clinical medicine · 2026Article
- Sleep improvement in patients with rheumatoid arthritis treated with upadacitinib in real-world practice: results from the SLEERA study.Arthritis research & therapy · 2026Observational
- Assessment of Pain Types in Recently Diagnosed Patients With Inflammatory Arthritis.Arthritis care & research · 2026Article
- Towards an individualised approach to pain management in inflammatory arthritis.Therapeutic advances in musculoskeletal disease · 2026Review
- The mediating role of sleep quality in the association between inflammatory disease activity and health-related quality of life in rheumatoid arthritis.Frontiers in medicine · 2026Article
- Unmet needs in patients with RA judged in remission by the rheumatologist: a semi-structured interview study.Rheumatology advances in practice · 2026Article
- Mapping the future: identifying research priorities in rheumatoid arthritis with the James Lind Alliance approach.BMC rheumatology · 2025Article
- Prevalence and Predictors of Residual Symptoms in Rheumatoid Arthritis Patients in SDAI Remission: A Cross-Sectional Study Using the Illustrated Okomarigoto Sheet.Clinical rheumatology · 2025Article
- Explainable machine learning identifies key quality-of-life-related predictors of arthritis status: evidence from the China health and retirement longitudinal study.Health and quality of life outcomes · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the nature and burden of residual disease in rheumatoid arthritis (RA) in patients who meet treatment targets. Second, for those who did not meet targets, to evaluate how much is due to patient symptoms.
methodsProspective and retrospective studies were searched in Medline, Embase, and Cochrane Library in the English language from January 1, 2008 to April 18, 2018; conference abstracts (from January 2016 to April 2018) and reference lists of relevant studies were also screened.
resultsOf 8,339 records identified, 55 were included in the review; 53 were unique studies, including 10 randomized controlled trials. Of these, 48 reported on patients who achieved low disease activity (LDA) or remission. Studies varied in population, treatment goals, and outcome reporting. The proportions of patients with residual symptoms in these studies varied by the definitions used for LDA or remission and were more often reported in patients with LDA than those in remission. The most commonly reported outcome measures were functional disability (n = 34 studies), tender or swollen joints (n = 18), pain (n = 17), patient global assessment (n = 15), and fatigue (n = 14). However, few studies reported the percentage of patients achieving a specific threshold, which could then be used to easily define the presence of residual symptoms.
conclusionResidual symptoms are present in some patients despite their achieving LDA or remission, highlighting an unmet need, especially with respect to improving pain, fatigue, and function. Standardized reporting in future observational studies would facilitate better understanding of this issue in defined RA populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.